Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma

Wirth, Andrew; Seymour, John F.; Hicks, Rodney J.; Ware, Robert E.; Fisher, Richard; Prince, Miles; MacManus, Michael; Ryan, Graeme B.; Januszewicz, Henry; Wolf, Max

doi:10.1016/s0002-9343(01)01117-2

Cited by 155 publications

(58 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12,13 However, lymphoma diagnosis by the WHO classification was not reported in these studies. Our data indicate that WHO classification of lymphomas is crucial in determining the utility of FDG-PET to image lymphomas.…”

Section: Resultsmentioning

confidence: 91%

Utility of FDG-PET scanning in lymphoma by WHO classification

Elstrom

Guan

Baker

et al. 2003

Blood

403

212

View full text Add to dashboard Cite

We retrospectively evaluated 18 fluoro-2-deoxyglucose positron emission tomography (FDG-PET) scans in 172 patients with lymphoma and correlated results with pathologic diagnosis using the World Health Organization (WHO) classification system. In total, FDG-PET detected disease in at least one site in 161 patients (94%) and failed to detect disease in 11 patients (6%). The most frequent lymphoma diagnoses were diffuse large Bcell lymphoma (LBCL; n ‫؍‬ 51), Hodgkin lymphoma (HL; n ‫؍‬ 47), follicular lymphoma (FL; n ‫؍‬ 42), marginal zone lymphoma (MZL; n ‫؍‬ 12), mantle cell lymphoma (MCL; n ‫؍‬ 7), and peripheral T-cell lymphoma (PTCL; n ‫؍‬ 5

show abstract

Section: Resultsmentioning

confidence: 91%

Utility of FDG-PET scanning in lymphoma by WHO classification

Elstrom

Guan

Baker

et al. 2003

Blood

403

212

View full text Add to dashboard Cite

show abstract

“…PET is increasingly being used to select lymphoma patients for RT and to delineate RT fields [114]. FDG-PET is significantly more accurate in both staging [115] and treatment response assessment [116] in both Hodgkin and non-Hodgkin [117] lymphomas than conventional structural imaging. PET data are increasingly being incorporated into the RT planning process [118].…”

Section: Lymphomamentioning

confidence: 99%

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007

MacManus

Nestle

Rosenzweig

et al. 2009

Radiotherapy and Oncology

333

197

View full text Add to dashboard Cite

show abstract

“…26 Fluorine 18 fluorodeoxyglucose-PET is important in staging of lymphoma; FDG-PET leads to a change in stage of disease in up to 20% to 40% of patients, and in 5% to 15% of patients, this changes the treatment choice. [27][28][29][30][31][32][33][34][35][36][37] At present, the use of FDG-PET scans in the staging of lymphoma is the standard of care in most patients.…”

Section: Current Use Of Pet Scans In Managing Lymphoma Stagingmentioning

confidence: 99%

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Ansell

Armitage

2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma. I n most patients with lymphoma, positron emission tomographic (PET) scans show abnormalities at diagnosis. Normal findings on the scan after therapy is highly predictive of a good prognosis, particularly in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and Hodgkin lymphoma. However, the optimal application of PET scans to the management of all patients with lymphoma remains problematic. The major controversies include the optimal timing of PET scans (for staging, during therapy, after completion of therapy, surveillance in remission), standardization of PET scan interpretation (visual interpretation compared with standard uptake value [SUV] calculation), what constitutes a positive PET scan result, and whether PET scans should be used to direct management (eg, does changing therapy in patients with positive findings on PET change outcome, should biopsies of sites with positive PET results be done routinely before a management change). Although a large body of literature addressing these topics exists, the studies are often difficult to compare, making definitive conclusions on all these issues difficult. The previously published studies often used different designs and variable reporting, making interpretation and comparison of the results difficult. In the early studies particularly, heterogeneous populations with different stages of disease and different histologic subtypes were included, making the clinical applicability of the studies' results difficult. More recent studies focusing on efforts to standardize the conduct and interpretation of PET scans and on riskadapted therapies based on interim PET scan results will, it is hoped, improve the management and outcome of patients with lymphoma. A literature search of PubMed from 1999 to 2011 was performed using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. We highlight the current standard use ...

show abstract

Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma

Cited by 155 publications

References 30 publications

Utility of FDG-PET scanning in lymphoma by WHO classification

Utility of FDG-PET scanning in lymphoma by WHO classification

Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Contact Info

Product

Resources

About